New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - epoetin beta 10000 [iu] (in 0.6ml) - solution for injection - 10000 iu/0.6ml - active: epoetin beta 10000 [iu] (in 0.6ml) excipient: calcium chloride dihydrate dibasic sodium phosphate dodecahydrate glutamic acid glycine isoleucine leucine monobasic sodium phosphate dihydrate phenylalanine polysorbate 20 sodium chloride threonine urea water for injection - - for the treatment of anaemia associated with chronic kidney disease in patients on dialysis and symptomatic patients not yet undergoing dialysis - for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks - for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. - to increase the yield of autologous blood from patients in a pre-donation programme initiated to avoid the use of homologous blood

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - epoetin beta 2000 [iu] (in 0.3ml) - solution for injection - 2000 iu/0.3ml - active: epoetin beta 2000 [iu] (in 0.3ml) excipient: calcium chloride dihydrate dibasic sodium phosphate dodecahydrate glutamic acid glycine isoleucine leucine monobasic sodium phosphate dihydrate phenylalanine polysorbate 20 sodium chloride threonine urea water for injection - - for the treatment of anaemia associated with chronic kidney disease in patients on dialysis and symptomatic patients not yet undergoing dialysis - for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks - for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. - to increase the yield of autologous blood from patients in a pre-donation programme initiated to avoid the use of homologous blood

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - epoetin beta 3000 [iu] (in 0.3ml) - solution for injection - 3000 iu/0.3ml - active: epoetin beta 3000 [iu] (in 0.3ml) excipient: calcium chloride dihydrate dibasic sodium phosphate dodecahydrate glutamic acid glycine isoleucine leucine monobasic sodium phosphate dihydrate phenylalanine polysorbate 20 sodium chloride threonine urea water for injection - - for the treatment of anaemia associated with chronic kidney disease in patients on dialysis and symptomatic patients not yet undergoing dialysis - for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks - for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. - to increase the yield of autologous blood from patients in a pre-donation programme initiated to avoid the use of homologous blood

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - epoetin beta 4000 [iu] (in 0.3ml) - solution for injection - 4000 iu/0.3ml - active: epoetin beta 4000 [iu] (in 0.3ml) excipient: calcium chloride dihydrate dibasic sodium phosphate dodecahydrate glutamic acid glycine isoleucine leucine monobasic sodium phosphate dihydrate phenylalanine polysorbate 20 sodium chloride threonine urea water for injection - - for the treatment of anaemia associated with chronic kidney disease in patients on dialysis and symptomatic patients not yet undergoing dialysis - for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks - for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. - to increase the yield of autologous blood from patients in a pre-donation programme initiated to avoid the use of homologous blood

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - epoetin beta 5000 [iu] (in 0.3 ml) - solution for injection - 5000 iu/0.3ml - active: epoetin beta 5000 [iu] (in 0.3 ml) excipient: calcium chloride dihydrate dibasic sodium phosphate dodecahydrate glutamic acid glycine isoleucine leucine monobasic sodium phosphate dihydrate phenylalanine polysorbate 20 sodium chloride threonine urea water for injection - - for the treatment of anaemia associated with chronic kidney disease in patients on dialysis and symptomatic patients not yet undergoing dialysis - for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks - for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. - to increase the yield of autologous blood from patients in a pre-donation programme initiated to avoid the use of homologous blood

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - epoetin beta 6000 [iu] (in 0.3ml) - solution for injection - 6000 iu/0.3ml - active: epoetin beta 6000 [iu] (in 0.3ml) excipient: calcium chloride dihydrate dibasic sodium phosphate dodecahydrate glutamic acid glycine isoleucine leucine monobasic sodium phosphate dihydrate phenylalanine polysorbate 20 sodium chloride threonine urea water for injection - - for the treatment of anaemia associated with chronic kidney disease in patients on dialysis and symptomatic patients not yet undergoing dialysis - for the prevention of anaemia of prematurity in infants with a birth weight of 750 g to 1500 g and a gestational age of less than 34 weeks - for the treatment of anaemia in patients with non-myeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. - to increase the yield of autologous blood from patients in a pre-donation programme initiated to avoid the use of homologous blood

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - epoetin beta - injection, solution - 30,000 iu - epoetin beta 30,000 iu/0.6 ml

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - epoetin beta - injection - 4000 iu/0.3 ml - epoetin beta 4000 iu/0.3 ml

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - epoetin beta - injection - 10000 iu/0.6 ml - epoetin beta 10000 iu/0.6 ml

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - epoetin beta - injection - 2000 iu/0.3 ml - epoetin beta 2000 iu/0.3 ml